Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System
Overview
Authors
Affiliations
Purpose: The American Joint Committee on Cancer (AJCC) recently proposed major revisions of the tumor-node-metastases (TNM) categories and stage groupings for cutaneous melanoma. Thirteen cancer centers and cancer cooperative groups contributed staging and survival data from a total of 30,450 melanoma patients from their databases in order to validate this staging proposal.
Patients And Methods: There were 17,600 melanoma patients with complete clinical, pathologic, and follow-up information. Factors predicting melanoma-specific survival rates were analyzed using the Cox proportional hazards regression model. Follow-up survival data for 5 years or longer were available for 73% of the patients.
Results: This analysis demonstrated that (1) in the T category, tumor thickness and ulceration were the most powerful predictors of survival, and the level of invasion had a significant impact only within the subgroup of thin (< or = 1 mm) melanomas; (2) in the N category, the following three independent factors were identified: the number of metastatic nodes, whether nodal metastases were clinically occult or clinically apparent, and the presence or absence of primary tumor ulceration; and (3) in the M category, nonvisceral metastases was associated with a better survival compared with visceral metastases. A marked diversity in the natural history of pathologic stage III melanoma was demonstrated by five-fold differences in 5-year survival rates for defined subgroups. This analysis also demonstrated that large and complex data sets could be used effectively to examine prognosis and survival outcome in melanoma patients.
Conclusion: The results of this evidence-based methodology were incorporated into the AJCC melanoma staging as described in the companion publication.
Sex differences in melanoma survival-a GEM study.
Murali T, Schwartz M, Reynolds A, Luo L, Ridgeway G, Busam K JNCI Cancer Spectr. 2025; 9(1).
PMID: 39799507 PMC: 11812020. DOI: 10.1093/jncics/pkaf005.
Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.
Prkacin I, Mokos M, Ferara N, Situm M Cancers (Basel). 2025; 16(24.
PMID: 39766118 PMC: 11727356. DOI: 10.3390/cancers16244219.
Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications.
Bida M, Miya T, Hull R, Dlamini Z Front Immunol. 2024; 15:1497522.
PMID: 39712007 PMC: 11659259. DOI: 10.3389/fimmu.2024.1497522.
Barriers to establishing teledermatoscopy in primary health care in Sweden.
Hernstrom N, Ingvar A BMC Prim Care. 2024; 25(1):417.
PMID: 39690402 PMC: 11653750. DOI: 10.1186/s12875-024-02678-w.
Musicante M, Ferrer J, Lin J, Patel T, Liu-Smith F Skin Health Dis. 2024; 4(6):e463.
PMID: 39624748 PMC: 11608879. DOI: 10.1002/ski2.463.